Hantavirus Antibody Program

About Ichor Biologics

Ichor Biologics is a private, preclinical-stage biotech founded in 2015, leveraging a unique platform that identifies protective human immune responses to infectious diseases to develop antibody therapeutics. The company's core technology integrates immunology assays, antigen presentation methods, and machine learning to discover and optimize antibodies, with initial validation in hantavirus. Ichor's strategy involves advancing programs to preclinical proof-of-concept to generate intellectual property for potential partnerships or licensing deals with larger industry players.

Therapeutic Areas